Cited 0 times in
Comparison of immunomodulative effects of histamine-2 receptor antagonists in gastric cancer patients: focus on the lymphoblastogenesis and cytotoxicity of peripheral blood mononuclear cells
DC Field | Value | Language |
---|---|---|
dc.contributor.author | 김원호 | - |
dc.contributor.author | 박인서 | - |
dc.contributor.author | 이상인 | - |
dc.date.accessioned | 2023-07-12T00:41:24Z | - |
dc.date.available | 2023-07-12T00:41:24Z | - |
dc.date.issued | 1994-12 | - |
dc.identifier.issn | 0192-0561 | - |
dc.identifier.uri | https://ir.ymlib.yonsei.ac.kr/handle/22282913/195263 | - |
dc.description.abstract | A proposed mechanism of the immunomodulative effects of histamine-2 receptor antagonist (H2-RA) has been considered to be the inhibition of suppressor T-lymphocyte activity, an increase in interleukin-2 production of helper T-lymphocytes, and an enhancement of natural killer cell activity. Since there is a lack of comparative data about the immunomodulative effects of various H2-RAs, cimetidine, ranitidine and famotidine on peripheral blood mononuclear cells (PBMC), study of the comparison of the actions of H2-RA will be required. We compared the immunomodulative effect of each H2-RA on PBMC in patients with gastric cancer. DNA synthesis, cytotoxicity of PBMC against K562 cells and gastric cancer cell lines, and the levels of supernatant soluble interleukin-2 receptor (sIL-2R) were measured after the addition of each H2-RA, respectively. Increased suppressor cell activities were attenuated and restored to the levels of normal controls by the addition of cimetidine to H2-RA. Statistically significant lymphoblastogenesis and cytotoxicity against K562 cells were observed only in cimetidine-treated PBMC (P < 0.05). Such effects were not observed in ranitidine- or famotidine-treated PBMC. Neither cimetidine- nor ranitidine-activated activated PBMC showed any significant cytotoxicity against gastric cancer cells. Significantly increased levels of sIL-2R were found in supernatants obtained from culture flasks treated with cimetidine or ranitidine and phytohemagglutinin (P < 0.01). A significant correlation was found between the cytotoxicity of cimetidine- or ranitidine-treated PBMC and supernatant sIL-2R (P < 0.05). In conclusion, the most strongly modulative substance among H2-RAs was cimetidine and the least modulative drug was famotidine.(ABSTRACT TRUNCATED AT 250 WORDS) | - |
dc.description.statementOfResponsibility | restriction | - |
dc.language | English | - |
dc.publisher | Elsevier Science | - |
dc.relation.isPartOf | INTERNATIONAL JOURNAL OF IMMUNOPHARMACOLOGY | - |
dc.rights | CC BY-NC-ND 2.0 KR | - |
dc.subject.MESH | Adjuvants, Immunologic / pharmacology* | - |
dc.subject.MESH | Adult | - |
dc.subject.MESH | Aged | - |
dc.subject.MESH | Cytotoxicity, Immunologic / drug effects* | - |
dc.subject.MESH | DNA / biosynthesis | - |
dc.subject.MESH | Female | - |
dc.subject.MESH | Histamine H2 Antagonists / pharmacology* | - |
dc.subject.MESH | Histamine H2 Antagonists / therapeutic use | - |
dc.subject.MESH | Humans | - |
dc.subject.MESH | Killer Cells, Natural / drug effects | - |
dc.subject.MESH | Killer Cells, Natural / immunology | - |
dc.subject.MESH | Lymphocyte Activation / drug effects* | - |
dc.subject.MESH | Male | - |
dc.subject.MESH | Middle Aged | - |
dc.subject.MESH | Receptors, Interleukin-2 / analysis | - |
dc.subject.MESH | Stomach Neoplasms / immunology* | - |
dc.title | Comparison of immunomodulative effects of histamine-2 receptor antagonists in gastric cancer patients: focus on the lymphoblastogenesis and cytotoxicity of peripheral blood mononuclear cells | - |
dc.type | Article | - |
dc.contributor.college | College of Medicine (의과대학) | - |
dc.contributor.department | Dept. of Internal Medicine (내과학교실) | - |
dc.contributor.googleauthor | Ki Baik Hahm | - |
dc.contributor.googleauthor | Sang In Lee | - |
dc.contributor.googleauthor | Joon Pyo Chung | - |
dc.contributor.googleauthor | Won Ho Kim | - |
dc.contributor.googleauthor | Jin Hong Kim | - |
dc.contributor.googleauthor | In Suh Park | - |
dc.identifier.doi | 10.1016/0192-0561(94)90077-9 | - |
dc.contributor.localId | A00774 | - |
dc.contributor.localId | A01626 | - |
dc.contributor.localId | A02828 | - |
dc.relation.journalcode | J03827 | - |
dc.identifier.pmid | 7705971 | - |
dc.identifier.url | https://www.sciencedirect.com/science/article/pii/0192056194900779 | - |
dc.contributor.alternativeName | Kim, Won Ho | - |
dc.contributor.affiliatedAuthor | 김원호 | - |
dc.contributor.affiliatedAuthor | 박인서 | - |
dc.contributor.affiliatedAuthor | 이상인 | - |
dc.citation.volume | 16 | - |
dc.citation.number | 12 | - |
dc.citation.startPage | 985 | - |
dc.citation.endPage | 993 | - |
dc.identifier.bibliographicCitation | INTERNATIONAL JOURNAL OF IMMUNOPHARMACOLOGY, Vol.16(12) : 985-993, 1994-12 | - |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.